The BET Inhibitor GS-5829 Targets Chronic Lymphocytic Leukemia Cells and Their Supportive Microenvironment

Despite major improvements in treatment outcome with novel targeted therapies, such as the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, chronic lymphocytic leukemia (CLL) remains incurable in the majority of patients. Activation of PI3K, NF-κB, and/or MYC has been linked to residual disease and...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ekaterina, ten Hacken, Elisa, Sivina, Mariela, Clarke, Astrid, Thompson, Philip A., Jain, Nitin, Ferrajoli, Alessandra, Estrov, Zeev, Keating, Michael J., Wierda, William G., Bhalla, Kapil N., Burger, Jan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272263/
https://www.ncbi.nlm.nih.gov/pubmed/31862959
http://dx.doi.org/10.1038/s41375-019-0682-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272263/
https://www.ncbi.nlm.nih.gov/pubmed/31862959
http://dx.doi.org/10.1038/s41375-019-0682-7

Ejemplares similares